Tuberculosis Diagnostics Test Market-By Test Type (Radiographic, Diagnostic Laboratory, Molecular Diagnostics, Detection of Latent Infection, Cytokine Detection Assay, Detection of Drug Resistance, Phage Assay), End-use-Global Forecast, 2024-2032

Global Tuberculosis Diagnostics Test Market will witness over 5.5% CAGR between 2024 and 2032, spurred by increased availability and efforts to enhance the affordability of these diagnostics. With tuberculosis remaining a global health concern, there is a pressing need for accurate and accessible diagnostic tools.

For instance, in September 2023, Danaher Corporation, the provider of the Xpert MTB/RIF molecular test for tuberculosis (TB) diagnosis, and rifampicin resistance detection, declared a reduction in the price of its standard TB test cartridge to $7.97. This marked a 20% decrease from the current $9.98 price in low- and middle-income countries in response to mounting international pressure for a 50% reduction. Danaher Corporation planned to offer the cartridges at a reduced rate to the Global Fund and less-developed countries qualifying for Cepheid's Global Access Programme.

Innovations in technology and manufacturing processes are driving down costs, making these tests more affordable and accessible, particularly in low-resource settings. As efforts to combat tuberculosis intensify, the demand for reliable diagnostics continues to grow, ensuring early detection and effective management of the disease.

The overall Tuberculosis Diagnostics Test Industry is classified based on the test type, end-user, and region.

Molecular diagnostics segment will undergo significant development from 2024 to 2032. Molecular tests, such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs), offer rapid and accurate detection of tuberculosis and drug resistance. Their ability to identify specific genetic material of the TB bacterium revolutionizes diagnosis, enabling early detection and treatment initiation. As healthcare systems prioritize efficient and precise diagnostics, the demand for molecular tests continues to grow, shaping the landscape of tuberculosis diagnosis worldwide.

Tuberculosis diagnostics test market size from the point-of-care testing segment will register a noteworthy CAGR from 2024 to 2032. With tuberculosis remaining a significant global health concern, the need for rapid and accessible diagnostic tools is paramount. POCT offers the advantage of quick results at the patient's bedside or in remote settings, facilitating prompt treatment initiation and reducing transmission rates. As healthcare systems emphasize early detection and intervention, the demand for POCT solutions in tuberculosis diagnostics continues to grow, driving market expansion and innovation.

Asia Pacific tuberculosis diagnostics test market will showcase a commendable CAGR from 2024 to 2032. With a significant portion of global tuberculosis cases occurring in Asia Pacific countries, there is a pressing demand for accurate and accessible diagnostic tests. Governments and healthcare organizations are investing in tuberculosis control programs, thus fueling the demand for diagnostic tools to aid in early detection and treatment. This trend underscores the pivotal role of the Asia Pacific region in shaping the trajectory of the tuberculosis diagnostics test market.

For instance, in October 2023, The National Tuberculosis Elimination Programme (NTEP) incorporated SerumMylab's domestically developed latent tuberculosis detection test into its initiatives to eradicate the infectious disease by 2025. This innovative test, known as Cy-TB, can identify latent infection before it progresses into an active disease. Meeting the TB elimination target by 2025 necessitates testing and treating latent TB infection (LTBI).